{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:08:04Z","timestamp":1778818084511,"version":"3.51.4"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T00:00:00Z","timestamp":1138752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>A 3-year, randomized, double-blind, placebo-controlled trial evaluated the effect of oral alendronate on the BMD of 64 adult patients with osteogenesis imperfecta. The mean increases in the lumbar spine BMD were 10.1 \u00b1 9.8% (p &amp;lt; 0.001) and 0.7 \u00b1 5.7% in the alendronate and placebo groups, respectively. Oral alendronate increases BMD in adult patients with osteogenesis imperfecta.<\/jats:p>\n               <jats:p>Introduction: This study evaluated the effect of oral alendronate on the BMD of adult patients with osteogenesis imperfecta.<\/jats:p>\n               <jats:p>Materials and Methods: We carried out a 3-year, randomized, double-blind, placebo-controlled trial of oral alendronate in 64 adult patients with osteogenesis imperfecta. The primary endpoint was the difference between the groups in the mean percent change in lumbar spine BMD at 3 years. Secondary outcomes included changes in BMD of total hip, vertebral and peripheral fracture incidence, pain, hearing loss, and bone turnover biochemical markers. Patients were treated daily with either placebo or 10 mg alendronate. All received 1 g of calcium and 800 IU of vitamin D daily.<\/jats:p>\n               <jats:p>Results: The mean \u00b1 SD increases in the lumbar spine BMD were 10.1 \u00b1 9.8% (p &amp;lt; 0.001) and 0.7 \u00b1 5.7% in the alendronate and placebo groups, respectively. Hip BMD increased in the alendronate group by 3.3 \u00b1 0.5% (p = 0.001) and decreased in the placebo group by 0.3 \u00b1 0.6%. The sample size was not sufficient to determine an effect of alendronate on fracture rate. A significant increase of the pain score was noted in the alendronate group (p = 0.04) in the intent-to-treat analysis but not in the per protocol analysis. There was no change in hearing in either group. Bone resorption and formation biochemical markers were significantly decreased in the alendronate group (p &amp;lt; 0.001). There were no differences in severe adverse effects between the groups, but there was an increase in nonsevere upper gastrointestinal effects in the alendronate group (p = 0.003).<\/jats:p>\n               <jats:p>Conclusions: Oral alendronate increases BMD and increase nonsevere gastrointestinal adverse effects but does not modify the hearing loss in adult patients with osteogenesis imperfecta. More studies are needed to evaluate an effect on the fracture rate.<\/jats:p>","DOI":"10.1359\/jbmr.051015","type":"journal-article","created":{"date-parts":[[2006,4,26]],"date-time":"2006-04-26T13:26:28Z","timestamp":1146057988000},"page":"300-306","source":"Crossref","is-referenced-by-count":89,"title":["Effects of Oral Alendronate on BMD in Adult Patients With Osteogenesis Imperfecta: A 3-Year Randomized Placebo-Controlled Trial"],"prefix":"10.1093","volume":"21","author":[{"given":"Guillaume","family":"Chevrel","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Bone Diseases, Edouard Herriot Hospital, Lyon France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Marie","family":"Schott","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Bone Diseases, Edouard Herriot Hospital, Lyon France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Fontanges","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Bone Diseases, Edouard Herriot Hospital, Lyon France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanne E","family":"Charrin","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Bone Diseases, Edouard Herriot Hospital, Lyon France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genevi\u00e8ve","family":"Lina-Granade","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Edouard Herriot Hospital, Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Duboeuf","sequence":"additional","affiliation":[{"name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale, Research Unit 403, Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Garnero","sequence":"additional","affiliation":[{"name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale, Research Unit 403, Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monique","family":"Arlot","sequence":"additional","affiliation":[{"name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale, Research Unit 403, Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claude","family":"Raynal","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Bone Diseases, Edouard Herriot Hospital, Lyon France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre J","family":"Meunier","sequence":"additional","affiliation":[{"name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale, Research Unit 403, Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2009,12,4]]},"reference":[{"key":"2024013019395421800_bib1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/jmg.16.2.101","article-title":"Genetic heterogeneity in osteogenesis imperfecta","volume":"16","author":"Sillence","year":"1979","journal-title":"J Med Genet"},{"key":"2024013019395421800_bib2","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(04)16051-0","article-title":"Osteogenesis imperfecta","volume":"363","author":"Rauch","year":"2004","journal-title":"Lancet"},{"key":"2024013019395421800_bib3","first-page":"293","article-title":"Consistent linkage of dominantly inherited osteogenesis imperfecta to the type I collagen loci: COL 1A1 and COL 1A2","volume":"46","author":"Sykes","year":"1990","journal-title":"Am J Hum Genet"},{"key":"2024013019395421800_bib4","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/BF00350961","article-title":"Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta","volume":"16","author":"Devogelaer","year":"1987","journal-title":"Skeletal Radiol"},{"key":"2024013019395421800_bib5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/01241398-198801000-00017","article-title":"Is APD a promising drug in the treatment of severe osteogenesis imperfecta","volume":"8","author":"Huaux","year":"1988","journal-title":"J Pediatr Orthop"},{"key":"2024013019395421800_bib6","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/00005792-199707000-00005","article-title":"Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis","volume":"76","author":"Brumsen","year":"1997","journal-title":"Medicine (Baltimore)"},{"key":"2024013019395421800_bib7","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","article-title":"Cyclic administration of pamidronate in children with severe osteogenesis imperfecta","volume":"339","author":"Glorieux","year":"1998","journal-title":"N Engl J Med"},{"key":"2024013019395421800_bib8","first-page":"1846","article-title":"Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age","volume":"85","author":"Plotkin","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2024013019395421800_bib9","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1136\/adc.86.5.356","article-title":"Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta","volume":"86","author":"Astrom","year":"2002","journal-title":"Arch Dis Child"},{"key":"2024013019395421800_bib10","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1210\/jc.2002-021371","article-title":"Osteogenesis imperfecta types I, III, and IV: Effect of pamidronate therapy on bone and mineral metabolism","volume":"88","author":"Rauch","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2024013019395421800_bib11","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1542\/peds.111.5.1030","article-title":"Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV","volume":"111","author":"Zeitlin","year":"2003","journal-title":"Pediatrics"},{"key":"2024013019395421800_bib12","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.bone.2003.11.019","article-title":"Intravenous pamidronate treatment in children with moderate to severe osteogenesis imperfecta: Assessment of indices of dual-energy X-ray absorptiometry and bone metabolic markers during the first year of therapy","volume":"34","author":"Arikoski","year":"2004","journal-title":"Bone"},{"key":"2024013019395421800_bib13","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(04)16101-1","article-title":"Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: A 2-year randomised placebo-controlled study","volume":"363","author":"Sakkers","year":"2004","journal-title":"Lancet"},{"key":"2024013019395421800_bib14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00223-001-1055-5","article-title":"The effect of intravenous pamidronate on bone mineral density, bone histomorphometry, and parameters of bone turnover in adults with type IA osteogenesis imperfecta","volume":"72","author":"Shapiro","year":"2003","journal-title":"Calcif Tissue Int"},{"key":"2024013019395421800_bib15","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1359\/jbmr.2003.18.1.126","article-title":"Intravenous neridronate in adults with osteogenesis imperfecta","volume":"18","author":"Adami","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2024013019395421800_bib16","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group","volume":"333","author":"Liberman","year":"1995","journal-title":"N Engl J Med"},{"key":"2024013019395421800_bib17","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"2024013019395421800_bib18","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","article-title":"Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. FIT Research Group","volume":"85","author":"Black","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2024013019395421800_bib19","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1056\/NEJM200008313430902","article-title":"Alendronate for the treatment of osteoporosis in men","volume":"343","author":"Orwoll","year":"2000","journal-title":"N Engl J Med"},{"key":"2024013019395421800_bib20","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJM198406283102602","article-title":"Osteogenesis imperfecta after the menopause","volume":"310","author":"Paterson","year":"1984","journal-title":"N Engl J Med"},{"key":"2024013019395421800_bib21","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00003086-196400330-00010","article-title":"Genetic and environmental factors in the etiology of congenital dislocation of the hip","volume":"33","author":"Carter","year":"1964","journal-title":"Clin Orthop"},{"key":"2024013019395421800_bib22","first-page":"99","article-title":"Evaluation of the calcium content of diet by frequential self-questionnaire","volume":"58","author":"Fardellone","year":"1991","journal-title":"Rev Rhum Mal Osteoartic"},{"key":"2024013019395421800_bib23","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/jbmr.5650110716","article-title":"Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis The Study of Osteoporotic Fractures Research Group","volume":"11","author":"Genant","year":"1996","journal-title":"J Bone Miner Res"},{"key":"2024013019395421800_bib24","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199807303390502","article-title":"Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group","volume":"339","author":"Saag","year":"1998","journal-title":"N Engl J Med"},{"key":"2024013019395421800_bib25","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1172\/JCI0215952","article-title":"The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta","volume":"110","author":"Rauch","year":"2002","journal-title":"J Clin Invest"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2FJBMR.051015","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/21\/2\/300\/56481141\/5650210212.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/21\/2\/300\/56481141\/5650210212.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T14:45:42Z","timestamp":1710341142000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/21\/2\/300-306\/7593442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2,1]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2009,12,4]]},"published-print":{"date-parts":[[2006,2,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.051015","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2006,2,1]]},"published":{"date-parts":[[2006,2,1]]}}}